Frank Misselwitz is currently Vice President and Head of Cardiovascular Development at Bayer Pharma AG, Wuppertal, Germany, where he has worked for 13 years.
After receiving his MD and an MSc in medical biophysics in 1981, Dr Misselwitz earned his PhD in 1984. His interest in thrombosis was first evident in his doctoral thesis on cellular biology of atherosclerosis and thrombosis. He has worked in the thrombosis field for over 30 years, initially as an active physician and director of the Haemostasis Laboratory at the Institute for Cardiovascular Research of the Academy of Sciences in Berlin, and later at various pharmaceutical companies.
He has been responsible for the worldwide clinical development of rivaroxaban since 2002. He was involved in the planning and execution of the phase II and III clinical studies, and is currently heavily involved in the planning and execution of late life cycle studies. In 2005 he became Vice President and Head of the Therapeutic Area Cardiovascular and Coagulation. Under his leadership recently Adempas (Riociguat) was successfully developed and approved to treat Pulmonary Arterial Hypertension and Chronic Thrombo-Embolic Pulmonary Hypertension.
Dr Misselwitz is the author of over 200 scientific publications in highly respected journals, and is a member of several international societies, including the American Society of Hematology and the American Heart Association.